Effect of renin-angiotensin aldosteron system blockers on postoperative atrial fibrillation

International Journal of Cardiology

Volumn 127, Issue 3, 2008, Pages 362-367

  Ozaydin, Mehmet ^a   Dede, Ozkan ^a   Varol, Ercan ^b   Kapan, Sahin ^a   Turker, Yasin ^a   Peker, Oktay ^a   Duver, Harun ^a   Ibrisim, Erdogan ^a  

^a SULEYMAN DEMIREL UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b ISPARTA STATE HOSPITAL   (Turkey)

Author keywords

Angiotensin converting enzyme inhibitors; Atrial fibrillation; Candesartan; Cardiopulmonary bypass

Indexed keywords

CANDESARTAN; CILAZAPRIL; FOSINOPRIL; LISINOPRIL; PERINDOPRIL; QUINAPRIL; RAMIPRIL;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; FEMALE; HEART ATRIUM FIBRILLATION; HEART VALVE SURGERY; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MITRAL VALVE REPLACEMENT; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ADULT; AGED; AGED, 80 AND OVER; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; CORONARY ARTERY BYPASS; FEMALE; HEART VALVE PROSTHESIS IMPLANTATION; HUMANS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; RENIN-ANGIOTENSIN SYSTEM; TETRAZOLES;

EID: 45849118755     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2007.05.012     Document Type: Article

References (32)

1. Creswell L.L., Schuessler R.B., Rosenbloom M., and Cox J.L. Hazards of postoperative atrial arrhythmias. Ann Thorac Surg 56 (1993) 539-549
2. Maisel W.H., Rawn J., and Stevenson W.G. Atrial fibrillation after cardiac surgery. Ann Intern Med 135 (2001) 1061-1073
3. Kumagai K., Nakashima H., and Saku K. The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model. Cardiovasc res 62 (2004) 105-111
4. Kamei M., Morita S., Hayashi Y., Kanmura Y., and Kuro M. Carvedilol versus metoprolol for the prevention of atrial fibrillation after off-pump coronary bypass surgery. Rationale and design of the carvedilol or metoprolol post-revascularization atrial fibrillation controlled trial (COMPACT). Cardiovasc Drugs Ther 20 (2006) 219-227
5. Almassi G.H., Schowalter T., Nicolosi A.C., et al. Atrial fibrillation after cardiac surgery: a major morbid event?. Ann Surg 226 (1997) 501-511
6. Aranski S.F., Shaw D.P., Adams D.H., Rizzo R.J., Couper G.S., and VanderVliet M. Predictors of atrial fibrillation after coronary artery surgery. Current trends and impact on hospital resources. Circulation 94 (1996) 390-397
7. Treggiari-Venzi M.M., Waeber J.L., Perneger T.V., Suter P.M., and Romand J.A. Intravenous amiodarone or magnesium sulfate is not cost-beneficial prophylaxis for atrial fibrillation after coronary artery bypass surgery. Br J Anaesth 85 (2000) 690-695
8. Villareal R.P., Hariharan R., Liu B.C., et al. Postoperative atrial fibrillation and mortality after coronary artery bypass surgery. J Am Coll Cardiol 43 (2004) 742-748
9. Ehrlich J.R., Hohnloser S.H., and Nattel S. Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence. Eur Heart J 27 (2006) 512-518
10. Maggioni A.P., Latini R., Carson P.E., et al. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J 149 (2005) 548-557
11. Wachtell K., Lehto M., Gerdts E., et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol. J Am Coll Cardiol 45 (2005) 712-719
12. Madrid A.H., Peng J., Zamora J., et al. The role of angiotensin receptor blockers and/or angiotensin converting enzyme inhibitors in the prevention of atrial fibrillation in patients with cardiovascular diseases: meta-analysis of randomized controlled clinical trials. Pacing Clin Electrophysiol 27 (2004) 1405-1410
13. Madrid A.H., Bueno M.G., Rebollo J.M., et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation 106 (2002) 331-336
14. Ueng K.C., Tsai T.P., Yu W.C., et al. Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Results of a prospective and controlled study. Eur Heart J 24 (2003) 2090-2098
15. Ruel M., Masters R.G., Rubens F.D., et al. Late incidence and determinants of stroke after aortic and mitral valve replacement. Ann Thorac Surg 78 (2004) 77-83
16. White C.M., Kluger J., Lertsburapa K., Faheem O., and Coleman C.I. Effect of preoperative angiotensin converting enzyme inhibitor or angiotensin receptor blocker use on the frequency of atrial fibrillation after cardiac surgery: a cohort study from the atrial fibrillation suppression trials II and III. Eur J Cardiothorac Surg 31 5 (May 2007) 818-821 [Electronic publication 2007 Mar 12]
17. Anne W., Willems R., Merwe N.V., Werf F.V., Ector H., and Heidbüchel H. Atrial fibrillation after radiofrequency ablation of atrial flutter: preventive effect of angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, and diuretics. Heart 90 (2004) 1025-1030
18. Biase M.D., Troccoli R., and Brunetti N.D. Non-antiarrhythmic drugs for the prevention of cardiac arrhythmias. Ital Heart J 6 (2005) 175-179
19. van der Harst P., Volbeda M., Voors A.A., et al. Vascular response to angiotensin II predicts long-term prognosis in patients undergoing coronary artery bypass grafting. Hypertension 44 (2004) 930-934
20. Ryckwaert F., Colson P., Ribstein J., Boccara G., and Guillon G. Haemodynamic and renal effects of intravenous enalaprilat during coronary artery bypass graft surgery in patients with ischaemic heart dysfunction. Br J Anaesth 86 (2001) 169-175
21. Ozaydin M., Dogan A., Varol E., et al. Statin use before by-pass surgery decreases the incidence and shortens the duration of postoperative atrial fibrillation. Cardiology 107 (2006) 117-121 [Electronic publication ahead of print]
22. Ozaydin M., Varol E., Aslan S.M., et al. Effect of atorvastatin on the recurrence rates of atrial fibrillation after electrical cardioversion. Am J Cardiol 97 (2006) 1490-1493
23. Chung M.K., Martin D.O., Sprecher D., et al. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation 104 (2001) 2886-2891
24. Ohtani K., Egashira K., Ihara Y., et al. Angiotensin II type 1 receptor blockade attenuates in-stent restenosis by inhibiting inflammation and progenitor cells. Hypertension (Aug 28 2006) [Electronic publication ahead of print]
25. Dahlof B., Devereux R.B., Kjeldsen S.E., et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359 (2002) 995-1003
26. Nakashima H., Kumagai K., Urata H., Gondo N., Ideishi M., and Arakawa K. Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. Circulation 101 (2000) 2612-2617
27. Moreno I., Caballero R., and Gonzalez T. Efectos del irbesartan sobre los canales de potasio responsables de la repolarizacion cardiaca humana. Rev Esp Cardiol 55 (2002) 148
28. Marin F., Pascual D.A., Roldan V., et al. Statins and postoperative risk of atrial fibrillation following coronary artery bypass grafting. Am J Cardiol 97 (2006) 55-60
29. Sasamura H., Kitamura Y., Nakamura M., Ryuzaki M., and Saruta T. Effects of the angiotensin receptor blocker candesartan on arterial stiffness and markers of extracellular matrix metabolism in patients with essential hypertension. Clin Exp Hypertens 28 (2006) 511-520
30. Kumagai K., Nakashima H., Urata H., Gondo N., Arakawa K., and Saku K. Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. J Am Coll Cardiol 41 (2003) 2197-2204
31. McMurray J.J., Andersson F.L., Stewart S., et al. resource utilization and costs in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. Eur Heart J 27 (2006) 1447-1458
32. Zanchettý A., and Elmfeld D. Findings and implications of the study on cognition and prognosis in the elderly (SCOPE) - a review. Blood Press 15 (2006) 71-79